Andreas Rimner1, Daniel E Spratt2, Marjorie G Zauderer3, Kenneth E Rosenzweig4, Abraham J Wu2, Amanda Foster2, Ellen D Yorke5, Prasad Adusumilli6, Valerie W Rusch6, Lee M Krug3. 1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: rimnera@mskcc.org. 2. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College, New York, New York. 4. Department of Radiation Oncology, Mount Sinai Medical Center, New York, New York. 5. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York. 6. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract
PURPOSE: We previously reported our technique for delivering intensity modulated radiation therapy (IMRT) to the entire pleura while attempting to spare the lung in patients with malignant pleural mesothelioma (MPM). Herein, we report a detailed pattern-of-failure analysis in patients with MPM who were unresectable or underwent pleurectomy/decortication (P/D), uniformly treated with hemithoracic pleural IMRT. METHODS AND MATERIALS: Sixty-seven patients with MPM were treated with definitive or adjuvant hemithoracic pleural IMRT between November 2004 and May 2013. Pretreatment imaging, treatment plans, and posttreatment imaging were retrospectively reviewed to determine failure location(s). Failures were categorized as in-field (within the 90% isodose line), marginal (<90% and ≥50% isodose lines), out-of-field (outside the 50% isodose line), or distant. RESULTS: The median follow-up was 24 months from diagnosis and the median time to in-field local failure from the end of RT was 10 months. Forty-three in-field local failures (64%) were found with a 1- and 2-year actuarial failure rate of 56% and 74%, respectively. For patients who underwent P/D versus those who received a partial pleurectomy or were deemed unresectable, the median time to in-field local failure was 14 months versus 6 months, respectively, with 1- and 2-year actuarial in-field local failure rates of 43% and 60% versus 66% and 83%, respectively (P=.03). There were 13 marginal failures (19%). Five of the marginal failures (38%) were located within the costomediastinal recess. Marginal failures decreased with increasing institutional experience (P=.04). Twenty-five patients (37%) had out-of-field failures. Distant failures occurred in 32 patients (48%). CONCLUSIONS: After hemithoracic pleural IMRT, local failure remains the dominant form of failure pattern. Patients treated with adjuvant hemithoracic pleural IMRT after P/D experience a significantly longer time to local and distant failure than patients treated with definitive pleural IMRT. Increasing experience and improvement in target delineation minimize the incidence of avoidable marginal failures.
PURPOSE: We previously reported our technique for delivering intensity modulated radiation therapy (IMRT) to the entire pleura while attempting to spare the lung in patients with malignant pleural mesothelioma (MPM). Herein, we report a detailed pattern-of-failure analysis in patients with MPM who were unresectable or underwent pleurectomy/decortication (P/D), uniformly treated with hemithoracic pleural IMRT. METHODS AND MATERIALS: Sixty-seven patients with MPM were treated with definitive or adjuvant hemithoracic pleural IMRT between November 2004 and May 2013. Pretreatment imaging, treatment plans, and posttreatment imaging were retrospectively reviewed to determine failure location(s). Failures were categorized as in-field (within the 90% isodose line), marginal (<90% and ≥50% isodose lines), out-of-field (outside the 50% isodose line), or distant. RESULTS: The median follow-up was 24 months from diagnosis and the median time to in-field local failure from the end of RT was 10 months. Forty-three in-field local failures (64%) were found with a 1- and 2-year actuarial failure rate of 56% and 74%, respectively. For patients who underwent P/D versus those who received a partial pleurectomy or were deemed unresectable, the median time to in-field local failure was 14 months versus 6 months, respectively, with 1- and 2-year actuarial in-field local failure rates of 43% and 60% versus 66% and 83%, respectively (P=.03). There were 13 marginal failures (19%). Five of the marginal failures (38%) were located within the costomediastinal recess. Marginal failures decreased with increasing institutional experience (P=.04). Twenty-five patients (37%) had out-of-field failures. Distant failures occurred in 32 patients (48%). CONCLUSIONS: After hemithoracic pleural IMRT, local failure remains the dominant form of failure pattern. Patients treated with adjuvant hemithoracic pleural IMRT after P/D experience a significantly longer time to local and distant failure than patients treated with definitive pleural IMRT. Increasing experience and improvement in target delineation minimize the incidence of avoidable marginal failures.
Authors: Jan Van de Steene; Nadine Linthout; Johan de Mey; Vincent Vinh-Hung; Cornelia Claassens; Marc Noppen; Arjan Bel; Guy Storme Journal: Radiother Oncol Date: 2002-01 Impact factor: 6.280
Authors: Gordon O Schoenfeld; Robert J Amdur; Christopher G Morris; Jonathan G Li; Russell W Hinerman; William M Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: Emilio Minatel; Marco Trovo; Jerry Polesel; Tania Baresic; Alessandra Bearz; Giovanni Franchin; Carlo Gobitti; Imad Abu Rumeileh; Annalisa Drigo; Paolo Fontana; Vittore Pagan; Mauro G Trovo Journal: Lung Cancer Date: 2013-10-27 Impact factor: 5.705
Authors: Kenneth E Rosenzweig; Marjorie G Zauderer; Benjamin Laser; Lee M Krug; Ellen Yorke; Camelia S Sima; Andreas Rimner; Raja Flores; Valerie Rusch Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-18 Impact factor: 7.038
Authors: V W Rusch; K Rosenzweig; E Venkatraman; L Leon; A Raben; L Harrison; M S Bains; R J Downey; R J Ginsberg Journal: J Thorac Cardiovasc Surg Date: 2001-10 Impact factor: 5.209
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316
Authors: A Botticella; G Defraene; K Nackaerts; C Deroose; J Coolen; P Nafteux; B Vanstraelen; S Joosten; L A W Michiels; S Peeters; D De Ruysscher Journal: Strahlenther Onkol Date: 2017-02-14 Impact factor: 3.621
Authors: Jeffrey S Souris; Shih-Hsun Cheng; Charles Pelizzari; Nai-Tzu Chen; Patrick La Riviere; Chin-Tu Chen; Leu-Wei Lo Journal: Appl Phys Lett Date: 2014-11-20 Impact factor: 3.791
Authors: Fauzia Shaikh; Marjorie G Zauderer; Donata von Reibnitz; Abraham J Wu; Ellen D Yorke; Amanda Foster; Weiji Shi; Zhigang Zhang; Prasad S Adusumilli; Kenneth E Rosenzweig; Lee M Krug; Valerie W Rusch; Andreas Rimner Journal: J Thorac Oncol Date: 2017-03-21 Impact factor: 15.609
Authors: Andreas Rimner; Marjorie G Zauderer; Daniel R Gomez; Prasad S Adusumilli; Preeti K Parhar; Abraham J Wu; Kaitlin M Woo; Ronglai Shen; Michelle S Ginsberg; Ellen D Yorke; David C Rice; Anne S Tsao; Kenneth E Rosenzweig; Valerie W Rusch; Lee M Krug Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Semi B Harrabi; Stefan A Koerber; Sebastian Adeberg; Sonja Katayama; Klaus Herfarth; Juergen Debus; Florian Sterzing Journal: Rep Pract Oncol Radiother Date: 2017-08-11